IC50 experiments revealed that overexpression of DECR1 increased the resistance of HCC cells to sorafenib (Figure 6J, Figure S6F), whereas downregulation of DECR1 had the opposite effect (Figure 6K, Figure S6G). The gene discussed is DECR1; the disease is hepatocellular carcinoma.